Affirm Holdings, Inc. Free cash flow increased by 175.4% to $325.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 106.6%, from $157.38M to $325.10M. Over 3 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 41.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$27.75M | $348.80M | -$462.07M | -$49.08M | -$86.15M | $20.06M | -$62.80M | -$84.79M | $63.09M | $35.57M | $161.68M | $30.51M | $152.72M | $268.11M | $157.38M | $23.52M | $320.21M | $118.03M | $325.10M |
| QoQ Change | — | >999% | -232.5% | +89.4% | -75.5% | +123.3% | -413.0% | -35.0% | +174.4% | -43.6% | +354.5% | -81.1% | +400.6% | +75.6% | -41.3% | -85.1% | >999% | -63.1% | +175.4% |
| YoY Change | — | — | — | — | -210.4% | -94.2% | +86.4% | -72.8% | +214.4% | +156.6% | +290.7% | — | +142.1% | +653.7% | -2.7% | -22.9% | +109.7% | -56.0% | +106.6% |